CN112449602A - 超高剂量率辐射和治疗剂的使用方法 - Google Patents

超高剂量率辐射和治疗剂的使用方法 Download PDF

Info

Publication number
CN112449602A
CN112449602A CN201980048106.XA CN201980048106A CN112449602A CN 112449602 A CN112449602 A CN 112449602A CN 201980048106 A CN201980048106 A CN 201980048106A CN 112449602 A CN112449602 A CN 112449602A
Authority
CN
China
Prior art keywords
dose
radiation
tumor
flash
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980048106.XA
Other languages
English (en)
Chinese (zh)
Inventor
R·帕里
E·阿贝尔
S·格德哈尼
S·曼斯菲尔德
P·库佩利安
D·昆蒂亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Varian Medical Systems Inc
Original Assignee
Varian Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Varian Medical Systems Inc filed Critical Varian Medical Systems Inc
Publication of CN112449602A publication Critical patent/CN112449602A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/103—Treatment planning systems
    • A61N5/1031—Treatment planning systems using a specific method of dose optimization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A61N5/1084—Beam delivery systems for delivering multiple intersecting beams at the same time, e.g. gamma knives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Primary Health Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Data Mining & Analysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Databases & Information Systems (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980048106.XA 2018-07-19 2019-07-19 超高剂量率辐射和治疗剂的使用方法 Pending CN112449602A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862700783P 2018-07-19 2018-07-19
US62/700,783 2018-07-19
PCT/US2019/042603 WO2020018904A1 (fr) 2018-07-19 2019-07-19 Méthodes d'utilisation de rayonnement à débit de dose ultra élevé et d'agents thérapeutiques

Publications (1)

Publication Number Publication Date
CN112449602A true CN112449602A (zh) 2021-03-05

Family

ID=67515191

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980048106.XA Pending CN112449602A (zh) 2018-07-19 2019-07-19 超高剂量率辐射和治疗剂的使用方法

Country Status (3)

Country Link
EP (1) EP3823618A1 (fr)
CN (1) CN112449602A (fr)
WO (1) WO2020018904A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9855445B2 (en) 2016-04-01 2018-01-02 Varian Medical Systems, Inc. Radiation therapy systems and methods for delivering doses to a target volume
US10183179B1 (en) 2017-07-21 2019-01-22 Varian Medical Systems, Inc. Triggered treatment systems and methods
US11590364B2 (en) 2017-07-21 2023-02-28 Varian Medical Systems International Ag Material inserts for radiation therapy
US11712579B2 (en) 2017-07-21 2023-08-01 Varian Medical Systems, Inc. Range compensators for radiation therapy
US10092774B1 (en) 2017-07-21 2018-10-09 Varian Medical Systems International, AG Dose aspects of radiation therapy planning and treatment
CN111479571A (zh) 2017-07-21 2020-07-31 瓦里安医疗系统公司 超高剂量率辐射和治疗剂的使用方法
US10549117B2 (en) 2017-07-21 2020-02-04 Varian Medical Systems, Inc Geometric aspects of radiation therapy planning and treatment
US10843011B2 (en) 2017-07-21 2020-11-24 Varian Medical Systems, Inc. Particle beam gun control systems and methods
EP3967367A1 (fr) 2017-11-16 2022-03-16 Varian Medical Systems Inc Sortie de faisceau améliorée et mise en forme de champ dynamique destinés à un système de radiothérapie
US10910188B2 (en) 2018-07-25 2021-02-02 Varian Medical Systems, Inc. Radiation anode target systems and methods
US11116995B2 (en) 2019-03-06 2021-09-14 Varian Medical Systems, Inc. Radiation treatment planning based on dose rate
US10814144B2 (en) 2019-03-06 2020-10-27 Varian Medical Systems, Inc. Radiation treatment based on dose rate
US11103727B2 (en) 2019-03-08 2021-08-31 Varian Medical Systems International Ag Model based PBS optimization for flash therapy treatment planning and oncology information system
US11090508B2 (en) 2019-03-08 2021-08-17 Varian Medical Systems Particle Therapy Gmbh & Co. Kg System and method for biological treatment planning and decision support
US10918886B2 (en) 2019-06-10 2021-02-16 Varian Medical Systems, Inc. Flash therapy treatment planning and oncology information system having dose rate prescription and dose rate mapping
US11291859B2 (en) 2019-10-03 2022-04-05 Varian Medical Systems, Inc. Radiation treatment planning for delivering high dose rates to spots in a target
US11865361B2 (en) 2020-04-03 2024-01-09 Varian Medical Systems, Inc. System and method for scanning pattern optimization for flash therapy treatment planning
US11541252B2 (en) * 2020-06-23 2023-01-03 Varian Medical Systems, Inc. Defining dose rate for pencil beam scanning
US20240009483A1 (en) * 2020-06-26 2024-01-11 Cancer Research Technology Limited Treatment Planning System
US11957934B2 (en) 2020-07-01 2024-04-16 Siemens Healthineers International Ag Methods and systems using modeling of crystalline materials for spot placement for radiation therapy
EP4112123A1 (fr) * 2021-07-02 2023-01-04 RaySearch Laboratories AB Planification et optimisation de thérapie à multimodalité
US20240091559A1 (en) * 2022-09-21 2024-03-21 Siemens Healthineers International Ag Enhanced dose rate/ultra-high dose rate radiation and spatially fractioned radiation therapy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101927065A (zh) * 2009-01-16 2010-12-29 北卡罗来纳大学查珀尔希尔分校 用于癌症治疗和研究的紧凑型微束放疗系统及方法
US20130274233A1 (en) * 2012-04-03 2013-10-17 President And Fellow Of Harvard College Modulators of hedgehog signaling pathway
US20150011817A1 (en) * 2013-07-03 2015-01-08 Yuxin Feng System and Method for Delivering an Ultra-High Dose of Radiation Therapy
CN105209070A (zh) * 2013-03-15 2015-12-30 瓦里安医疗系统公司 用于放射疗法的生物标志物
US9636525B1 (en) * 2011-02-15 2017-05-02 Velayudhan Sahadevan Method of image guided intraoperative simultaneous several ports microbeam radiation therapy with microfocus X-ray tubes
CN111479571A (zh) * 2017-07-21 2020-07-31 瓦里安医疗系统公司 超高剂量率辐射和治疗剂的使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006039569A1 (fr) * 2004-09-30 2006-04-13 The University Of Chicago Polytherapie d'inhibiteurs hedgehog, de rayonnement et d'agents chimiotherapeutiques
TW200948380A (en) 2008-04-11 2009-12-01 Galaxy Biotech Llc Combination of HGF inhibitor and PTEN agonist to treat cancer
US7801270B2 (en) 2008-06-19 2010-09-21 Varian Medical Systems International Ag Treatment plan optimization method for radiation therapy
CN105358217A (zh) * 2013-06-18 2016-02-24 杜克大学 在特定治疗标准及特定治疗参数下用于特定患者放射治疗计划的系统和方法
US10080911B2 (en) * 2015-09-10 2018-09-25 Varian Medical Systems, Inc. Knowledge-based spatial dose metrics and methods to generate beam orientations in radiotherapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101927065A (zh) * 2009-01-16 2010-12-29 北卡罗来纳大学查珀尔希尔分校 用于癌症治疗和研究的紧凑型微束放疗系统及方法
US9636525B1 (en) * 2011-02-15 2017-05-02 Velayudhan Sahadevan Method of image guided intraoperative simultaneous several ports microbeam radiation therapy with microfocus X-ray tubes
US20130274233A1 (en) * 2012-04-03 2013-10-17 President And Fellow Of Harvard College Modulators of hedgehog signaling pathway
CN105209070A (zh) * 2013-03-15 2015-12-30 瓦里安医疗系统公司 用于放射疗法的生物标志物
US20150011817A1 (en) * 2013-07-03 2015-01-08 Yuxin Feng System and Method for Delivering an Ultra-High Dose of Radiation Therapy
CN111479571A (zh) * 2017-07-21 2020-07-31 瓦里安医疗系统公司 超高剂量率辐射和治疗剂的使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DANIEL E.等: "Long-term Survival and Toxicity in Patients Treated With High-Dose Intensity Modulated Radiation Therapy for Localized Prostate Cancer" *
S. TECKIE等: "Ultra-high-dose Stereotactic Body Radiation Therapy (SBRT) is Feasible for Tumors in the Head and Neck (HN)" *
VINCENT FAVAUDON等: "Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice" *

Also Published As

Publication number Publication date
EP3823618A1 (fr) 2021-05-26
WO2020018904A1 (fr) 2020-01-23
WO2020018904A9 (fr) 2020-04-16

Similar Documents

Publication Publication Date Title
US11771920B2 (en) Methods of use of ultra-high dose rate radiation and therapeutic agent
CN112449602A (zh) 超高剂量率辐射和治疗剂的使用方法
Schoenfeld et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD (L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
JP7343565B2 (ja) 正規化バイオマーカースコアからがん治療を特定するためのシステム及び方法
Herter-Sprie et al. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer
EP3471752B1 (fr) Modulateurs immunitaires en combinaison avec un traitement par rayonnement
US10844437B2 (en) Biomarkers for radiation treatment
Patel et al. Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition
Breen et al. Radiation and immunotherapy: emerging mechanisms of synergy
US20200108066A1 (en) Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors
Buglione et al. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with “curative” intent
Yhim et al. Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): An open-label phase I/II trial
Ciardiello et al. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival
Elez et al. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC
Farren et al. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemo-and radiotherapy
Kischuk Targeting of Suppressive Myeloid Cells via Small Molecule Immunomodulators
Balkwill PG 4.01 Tumor–stroma crosstalk: targeting stroma and inflammation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination